Erratum to: Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial (Graefes Arch Clin Exp Ophthalmol, 10.1007/s00417-016-3431-x);Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 255, Issue 1, 2017, Pages 77-87

  Eter, Nicole ^a,f   Mohr, Andreas ^b,f   Wachtlin, Joachim ^c,f   Feltgen, Nicolas ^d   Shirlaw, Andrew ^e   Leaback, Richard ^e   For the German Ozurdex in RVO Real World Study Group, ^f   Asadi, Ali ^f   Bator Banasik, Elisabeth ^f   Bayati, Peyman ^f   Beeke, Erik ^f   Cordes, Andreas K ^f   Dave, Hita Tushar ^f   Elshinnawi, Ahmed ^f   Engelmann, Katrin ^f   Entenmann, Beatrix ^f   Foja, Christian ^f   Zeitz, Philipp Franko ^f   Gross, Anna ^f   Guthoff, Rainer ^f   Höh, Helmut ^f   Khaireddin, Riad ^f   Kretschmann, Ulf ^f   Kretz, Florian ^f   Liekfeld, Anja ^f   Neugebauer, Andreas ^f   Padge, Björn ^f   Reinking, Uwe ^f   Schade, Bernd ^f   Schell, David ^f   Schrecker, Jens ^f   Schuart, Claudia ^f   Schumacher, Annegret ^f   Singh, Pankaj ^f   Wrede, Julia ^f   more..

^a INST OF REPRO MED OF THE UNIV   (Germany)

^b Krankenhaus St Joseph Stift Bremen   (Germany)

^c Sankt Gertrauden Krankenhaus   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e ALLERGAN PLC   (United States)

^f NONE

Author keywords

Branch retinal vein occlusion; Central retinal thickness; Central retinal vein occlusion; Dexamethasone; Intravitreal; Macular edema

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; RANIBIZUMAB; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; BRANCH RETINAL VEIN OCCLUSION; CATARACT; CATARACT EXTRACTION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CILIARY DISK; CLINICAL EVALUATION; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; CRYOCOAGULATION; DEVICE SAFETY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION STUDY; FEMALE; FOLLOW UP; GERMANY; GLAUCOMA; HUMAN; IMMUNOTHERAPY; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; LASER SURGERY; LOW LEVEL LASER THERAPY; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOEXFOLIATION; RETREATMENT; SIDE EFFECT; TRABECULOPLASTY; VISUAL ACUITY CHART; VITRECTOMY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECTS; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINAL VEIN OCCLUSION; TIME FACTOR; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

AGED; DEXAMETHASONE; DRUG IMPLANTS; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MALE; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84979698204     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-016-3568-7     Document Type: Erratum

References (23)

1. Rehak M, Wiedemann P (2010) Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 8:1886–1894. doi:10.1111/j.1538-7836.2010.03909.x
2. Adelman RA, Parnes AJ, Bopp S, Saad Othman I, Ducournau D (2015) Strategy for the management of macular edema in retinal vein occlusion: the European VitreoRetinal Society macular edema study. Biomed Res Int 2015:870987. doi:10.1155/2015/870987
3. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, Welty D (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80–86. doi:10.1167/iovs.10-5285
4. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–.e3. doi:10.1016/j.ophtha.2010.03.032
5. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW (2012) Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 119:1190–1198. doi:10.1016/j.ophtha.2011.12.028
6. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM, Li J (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118:2453–2460. doi:10.1016/j.ophtha.2011.05.014
7. Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, Isaico R, Romanet JP, Creuzot-Garcher C (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Graefes Arch Clin Exp Ophthalmol 253:2095–102. doi:10.1007/s00417-015-2947-9
8. Gregori NZ, Feuer W, Rosenfeld PJ (2010) Novel method for analyzing Snellen visual acuity measurements. Retina 30:1046–1050. doi:10.1097/IAE.0b013e3181d87e04
9. Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA study). Retina 34:342–351. doi:10.1097/IAE.0b013e318297f842
10. Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA, Oliver A, Rabinovitch T, Sheidow TG, Tourville E, Wittenberg LA, Sigouin C, Baptiste DC (2015) Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 9:1255–1268. doi:10.2147/opth.s80500
11. Tservakis I, Koutsandrea C, Papaconstantinou D, Paraskevopoulos T, Georgalas I (2014) Safety and efficacy of dexamethasone intravitreal implant (Ozurdex) for the treatment of persistent macular edema secondary to retinal vein occlusion in eyes previously treated with anti-vascular endothelial growth factors. Curr Drug Saf 10:145–151
12. Bezatis A, Spital G, Hohn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH (2013) Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up — the SOLO study. Acta Ophthalmol 91:e340–e347. doi:10.1111/aos.12020
13. Augustin AJ, Holz FG, Haritoglou C, Mayer WJ, Bopp S, Scheuerle AF, Maier M, Sekundo W, Sandner D, Shirlaw A, Hattenbach LO (2015) Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica 233:18–26. doi:10.1159/000368840
14. Reid GA, Sahota DS, Sarhan M (2015) Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. Retina 35:1647–1655. doi:10.1097/iae.0000000000000524
15. Veritti D, Macor S, Lanzetta P (2014) Early effects of dexamethasone implant on macular morphology and visual function in patients with macular edema secondary to retinal vein occlusion. Ophthalmologica 232:144–148. doi:10.1159/000366232
16. Kuppermann BD, Haller JA, Bandello F, Loewenstein A, Jiao J, Li XY, Whitcup SM (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749. doi:10.1097/iae.0000000000000167
17. Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, Parravano MC, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A (2014) Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol 24:1–9. doi:10.5301/ejo.5000376
18. Fortoul V, Denis P, Kodjikian L (2015) Anatomical and functional recurrence after dexamethasone intravitreal implants: a 6-month prospective study. Eye (Lond) 29:769–775. doi:10.1038/eye.2015.36
19. ®) for retinal vein occlusion. Ophthalmologica 229:21–25. doi:10.1159/000342160
20. Mathew R, Pearce E, Muniraju R, Abdel-Hay A, Sivaprasad S (2014) Monthly OCT monitoring of Ozurdex for macular oedema related to retinal vascular diseases: re-treatment strategy (OCTOME Report 1). Eye (Lond) 28:318–326. doi:10.1038/eye.2013.287
21. Bandello F, Parravano M, Cavallero E, Cascavilla ML, Triolo G, Querques L, Borrelli E, Giorno P, Varano M, Lattanzio R, Querques G (2015) Prospective evaluation of morphological and functional changes after repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion. Ophthalmic Res 53:207–216. doi:10.1159/000381187
22. Singer MA, Capone A Jr, Dugel PU, Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA (2015) Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 15:33. doi:10.1186/s12886-015-0018-y
23. Jonas J, Paques M, Mones J, Glacet-Bernard A (2010) Retinal vein occlusions. Dev Ophthalmol 47:111–135. doi:10.1159/000320076